Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups

• Published in: Blood Vol. 89; no. 11; pp. 4167 - 4174
• Main Authors: TURBAY, D, LIEBERMAN, J, ALPER, C. A, DELGADO, J. C, CORZO, D, YUNIS, J. J, YUNIS, E. J
• Format: Journal Article
• Language: English
• Published: Washington, DC The Americain Society of Hematology 01.06.1997
• Subjects: Agranulocytosis - chemically induced; Agranulocytosis - ethnology; Agranulocytosis - genetics; Antipsychotic Agents - adverse effects; Biological and medical sciences; Clozapine - adverse effects; Drug toxicity and drugs side effects treatment; Europe - ethnology; Female; Gene Frequency; Genetic Linkage; Humans; Jews; Major Histocompatibility Complex - genetics; Male; Medical sciences; Pharmacology. Drug treatments; Polymorphism, Genetic; Toxicity: blood; Tumor Necrosis Factor-alpha - genetics; United States - ethnology; United States; Europe; Human; HLA-System; Genetic inheritance; Leukopenia; Psychotropic; Toxicity; Major histocompatibility system; Agranulocytosis; Cytokine; Class II histocompatibility antigen; Hemopathy; Clozapine; Ethnic group; Allele; Tumor necrosis factor; Microsatellite DNA; Risk factor; Antipsychotic; Jew; Neutropenia; Polymorphism
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.v89.11.4167

Genes of the major histocompatibility complex (MHC) are associated with susceptibility to different immune and nonimmune mediated diseases. We had reported that the drug adverse reaction, clozapine-induced agranulocytosis (CA), is associated with different HLA types and HSP70 variants in Ashkenazi Jewish and non-Jewish patients, suggesting that a gene within the MHC region is associated with CA. This study was designed to find common genetic markers for this disorder in both ethnic groups. The tumor necrosis factor (TNF) microsatellites d3 and b4 were found in higher frequencies in both Jewish and non-Jewish patients: 51 of 66 (77%) and 48 of 66 (57%), respectively. Comparisons of these frequencies with those of controls, 28 of 66 (42%) and 18 of 66 (27%), were statistically significant (corrected P value = .001 for the d3 allele and .0005 for the b4 allele). On the other hand, the TNF microsatellite b5 was underrepresented in the group of patients, 9 of 66 (14%), when compared with the control subjects, 43 of 66 (65%) (corrected P value = .0005), probably related to protection from CA. Our results show a strong association of some genetic variants of the TNF loci with susceptibility to CA in two different ethnic groups suggesting involvement of TNF and/or associated gene(s) products in the pathogenesis of this hematologic-drug adverse reaction.